RxDoctor Payments Data

Henry Kearse, MD

Dermatology · Summerville, SCNPI 1538247663

Payments from drug & device makers

$821in general payments, 2019–2025

Across 33 payments — averaging $24.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Incyte Corporation$167
  • AbbVie$133
  • E.r. Squibb & Sons, L.L.C.$121
  • Regeneron Healthcare Solutions, Inc.$79
  • LEO Pharma Inc.$44
  • Sanofi$42
  • plus $236 from 8 others

What the payments were for

  • Food & beverage$821100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$821 in reported general payments places this provider in the 25th percentile of 203 dermatology providers in South Carolina.

See all dermatology providers in South Carolina

Medicare billing

Part B allowed, 2024
$217,832
Medicare patients
857
Services billed
3,249

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab117$611,554
Humira(Cf) PenAdalimumab35$333,981
Skyrizi PenRisankizumab-Rzaa15$279,248
Cosentyx Sensoready (2 Pens)Secukinumab27$179,895
Cosentyx Unoready PenSecukinumab18$161,289
Dupixent SyringeDupilumab37$153,431
Taltz AutoinjectorIxekizumab17$140,915
Humira PenAdalimumab14$93,208
Cosentyx (2 Syringes)Secukinumab15$76,094
OpzeluraRuxolitinib Phosphate11$22,464
Clobetasol Propionate112$4,776
Tacrolimus34$3,232
Desonide25$1,545
Triamcinolone Acetonide97$1,266
Mometasone Furoate69$1,226

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisCosentyx (2 Syringes)$38$76,09415 claims
Incyte CorporationOpzelura$167$22,46411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 203 dermatology providers in South Carolina.

Other dermatology in Summerville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →